It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Esophageal squamous precancerous lesions (ESPL) are the precursors of esophageal squamous cell carcinoma (ESCC) including low-grade and high-grade intraepithelial neoplasia. Due to the absence of molecular indicators, which ESPL will eventually develop into ESCC and thus should be treated is not well defined. Indicators, for predicting risks of ESCC at ESPL stages, are an urgent need. We perform spatial whole-transcriptome atlas analysis, which can eliminate other tissue interference by sequencing the specific ESPL regions. In this study, the expression of TAGLN2 significantly increases, while CRNN expression level decreases along the progression of ESCC. Additionally, TAGLN2 protein level significantly increases in paired after-progression tissues compared with before-progression samples, while CRNN expression decreases. Functional studies suggest that TAGLN2 promotes ESCC progression, while CRNN inhibits it by regulating cell proliferation. Taken together, TAGLN2 and CRNN are suggested as candidate indicators for the risk of ESCC at ESPL stages.
Understanding the molecular changes in the transition from esophageal squamous precancerous lesions (ESPL) to esophageal squamous cell carcinoma (ESCC) remains essential. Here, the authors analyze ESPL samples using spatial transcriptomics and reveal expression changes in TAGLN2 and CRNN during progression to ESCC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Zhengzhou University, Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou, China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846); China-US (Henan) Hormel Cancer Institute, Zhengzhou, China (GRID:grid.506924.c)
2 China-US (Henan) Hormel Cancer Institute, Zhengzhou, China (GRID:grid.506924.c); Affiliated Cancer Hospital of Zhengzhou University, Department of Pathology, Zhengzhou, China (GRID:grid.414008.9) (ISNI:0000 0004 1799 4638); Zhengzhou University, Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced Biomedical Sciences, Zhengzhou, China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846)
3 China-US (Henan) Hormel Cancer Institute, Zhengzhou, China (GRID:grid.506924.c)
4 Zhengzhou University, Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou, China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846); China-US (Henan) Hormel Cancer Institute, Zhengzhou, China (GRID:grid.506924.c); Zhengzhou University, Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced Biomedical Sciences, Zhengzhou, China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846)
5 Zhengzhou University, Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou, China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846); China-US (Henan) Hormel Cancer Institute, Zhengzhou, China (GRID:grid.506924.c); Zhengzhou University, Tianjian Laboratory of Advanced Biomedical Sciences, Institute of Advanced Biomedical Sciences, Zhengzhou, China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846); The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou, China (GRID:grid.207374.5); Zhengzhou University, State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou, China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846)